Additionally, several preclinical studies have shown that the genetic deletion of CD5 in CAR and TCR T-cells enhances expansion, persistence, and cytotoxicity in both solid tumor and hematological malignancy models [48,49]. This evidence concerns the gene CD5 and hematologic disorder.